CDTTW

Conduit Pharmaceuticals Inc. Warrant

0.0098 USD
+0.0011
12.64%
Updated May 20, 3:15 PM EDT
1 day
12.64%
5 days
2.08%
1 month
40.00%
3 months
-11.71%
6 months
10.11%
Year to date
48.48%
1 year
-83.67%
5 years
-94.24%
10 years
-94.24%
 

About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Employees: 6

0
Funds holding %
of 7,202 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

301% more capital invested

Capital invested by funds: $60.3K [Q4 2024] → $242K (+$182K) [Q1 2025]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 18 [Q4 2024] → 19 (+1) [Q1 2025]

0.79% less ownership

Funds ownership: 6.33% [Q4 2024] → 5.54% (-0.79%) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for CDTTW.

Financial journalist opinion

We haven’t received any recent news articles for CDTTW.

Charts implemented using Lightweight Charts™